Zdrowie i gospodarka · 17/09/2014

FDA Releases Draft Guidance on Refusing ANDA Submissions Due to Impurity Limits

The FDA has made available a draft guidance to help pharmaceutical companies prepare for submissions of abbreviated new drug applications (ANDAs) that may be rejected if they fail to properly justify impurity limits.